Oramed Pharmaceuticals CEO Nadav Kidron's 2018 pay jumps 34% to $1.6M

Oramed Pharmaceuticals reports 2018 executive compensation

By ExecPay News

Published: August 6, 2019

Oramed Pharmaceuticals reported fiscal year 2018 executive compensation information on August 6, 2019.
In 2018, three executives at Oramed Pharmaceuticals received on average a compensation package of $882K, a 15% decrease compared to previous year.
Average pay of disclosed executives at Oramed Pharmaceuticals
Nadav Kidron, Chief Executive Officer, received $1.6M in total, which increased by 34% compared to 2017. 34% of Kidron's compensation, or $523K, was in option awards. Kidron also received $149K in bonus, $436K in salary, as well as $442K in other compensation.
Miriam Kidron, Chief Scientific Officer, received a compensation package of $587K, which decreased by 53% compared to previous year. 47% of the compensation package, or $274K, was in salary.
Joshua Hexter, Chief Operating Officer, earned $508K in 2018, a 27% decrease compared to previous year.
Oramed Pharmaceuticals' fiscal year ends on August 31.

Related executives

Nadav Kidron

Oramed Pharmaceuticals

Chief Executive Officer

Miriam Kidron

Oramed Pharmaceuticals

Chief Scientific Officer

Joshua Hexter

Oramed Pharmaceuticals

Chief Operating Officer

You may also like

Source: SEC filing on August 6, 2019.